Sign In
Buy CTSO
$0.489
+0.0090 (+1.88%)
At Close: Jun 03, 2026
PRINCETON, N.J. , Oct. 28, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
07:00am, Monday, 29'th Sep 2025
PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Provides DrugSorb-ATR Regulatory Update
07:00am, Tuesday, 16'th Sep 2025
PRINCETON, N.J. , Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
PRINCETON, N.J. , Sept. 8, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Friday, 05'th Sep 2025
PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
07:00am, Wednesday, 20'th Aug 2025
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J. , Aug. 20, 2025 /PRNew
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
01:22pm, Friday, 08'th Aug 2025
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Peter J. Mariani - Chief Financial Officer Phillip P.
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update
04:00pm, Thursday, 07'th Aug 2025
PRINCETON, N.J. , Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents Leads a New Era in Sepsis Treatment
07:00am, Thursday, 31'st Jul 2025
CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10 th PRINCETON, N.J. , July 31,
CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Tuesday, 29'th Jul 2025
PRINCETON, N.J. , July 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
07:00am, Wednesday, 02'nd Jul 2025
PRINCETON, N.J. , July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardia
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
07:00am, Tuesday, 24'th Jun 2025
PRINCETON, N.J. , June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents to Participate at the Jefferies Global Healthcare Conference
07:00am, Thursday, 29'th May 2025
PRINCETON, N.J. , May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using bl
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
09:27am, Thursday, 22'nd May 2025
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J. , Ma
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
09:37pm, Wednesday, 14'th May 2025
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis
